AR108975A1 - ANTIBODIES WITH LOW IMMUNOGENICITY AND ITS USES - Google Patents

ANTIBODIES WITH LOW IMMUNOGENICITY AND ITS USES

Info

Publication number
AR108975A1
AR108975A1 ARP170101865A ARP170101865A AR108975A1 AR 108975 A1 AR108975 A1 AR 108975A1 AR P170101865 A ARP170101865 A AR P170101865A AR P170101865 A ARP170101865 A AR P170101865A AR 108975 A1 AR108975 A1 AR 108975A1
Authority
AR
Argentina
Prior art keywords
antibodies
low immunogenicity
immunogenicity
methods
binding fragments
Prior art date
Application number
ARP170101865A
Other languages
Spanish (es)
Inventor
Hari Hariharan
Jeonghoon Sun
Bellos Hadjivassiliou
Lawrence Dearth
Jeffrey Johnson
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR108975A1 publication Critical patent/AR108975A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Anticuerpos y fragmentos de fijación al antígeno de estos con baja inmunogenicidad o sin inmunogenicidad en seres humanos y, opcionalmente, con propiedades de fabricación deseadas. También composiciones que comprenden tales anticuerpos o fragmentos de fijación al antígeno, métodos para usar tales anticuerpos y métodos para fabricar tales anticuerpos.Antibodies and antigen-binding fragments thereof with low immunogenicity or no immunogenicity in humans and, optionally, with desired manufacturing properties. Also compositions comprising such antibodies or antigen binding fragments, methods for using such antibodies and methods for making such antibodies.

ARP170101865A 2016-07-06 2017-07-05 ANTIBODIES WITH LOW IMMUNOGENICITY AND ITS USES AR108975A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
AR108975A1 true AR108975A1 (en) 2018-10-17

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101865A AR108975A1 (en) 2016-07-06 2017-07-05 ANTIBODIES WITH LOW IMMUNOGENICITY AND ITS USES

Country Status (19)

Country Link
US (1) US11427632B2 (en)
EP (1) EP3481862A4 (en)
JP (1) JP7120989B2 (en)
KR (1) KR20190035737A (en)
CN (1) CN109689684B (en)
AR (1) AR108975A1 (en)
AU (1) AU2017292752B2 (en)
BR (1) BR112019000166A2 (en)
CA (1) CA3029977A1 (en)
CL (1) CL2019000019A1 (en)
CO (1) CO2019001112A2 (en)
EA (1) EA201990218A1 (en)
EC (1) ECSP19008417A (en)
IL (1) IL264009A (en)
MX (1) MX2019000172A (en)
SG (1) SG11201811788SA (en)
TW (1) TW201811824A (en)
WO (1) WO2018009499A1 (en)
ZA (1) ZA201900070B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020001679A2 (en) 2017-08-02 2020-07-21 Phanes Therapeutics, Inc. anti-cd47 antibodies and their uses
KR102115300B1 (en) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 Antibody library and Screening Method of Antibody by Using the Same
TW202104260A (en) 2019-04-05 2021-02-01 美商西建公司 Engineering of an antibody for tumor-selective binding of cd47
JP2022535286A (en) 2019-06-07 2022-08-05 エーエルエックス オンコロジー インコーポレイテッド Methods and reagents for reducing interference of drugs that bind CD47 in serological assays
JP2023545983A (en) 2020-10-07 2023-11-01 セルジーン コーポレイション Bispecific antibody therapy for lymphoid malignancy conditions
JP2023552375A (en) 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド Multimers for reducing interference of drugs that bind to CD47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
JPH07503124A (en) 1991-06-14 1995-04-06 ゾーマ・コーポレーション Antibody fragments and their complexes produced by microorganisms
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
DE69621940T2 (en) * 1995-08-18 2003-01-16 Morphosys Ag PROTEIN - / (POLY) PEPTIDE LIBRARIES
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (en) 2001-07-12 2005-09-30 Jefferson Foote Super humanized antibodies.
KR20120035234A (en) * 2003-04-11 2012-04-13 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
CN100453556C (en) 2003-10-16 2009-01-21 麦克罗梅特股份公司 Multispecific deimmunized CD3-binders
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
BRPI0610912A2 (en) * 2005-06-01 2008-12-02 Micromet Ag anti-il2 antibodies
AU2007245181A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-Met
CA2832111A1 (en) 2006-12-20 2008-07-03 Mmrglobal, Inc. Antibodies and methods for making and using them
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
MX352871B (en) 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Method for decreasing immunogenicity.
JP5992340B2 (en) * 2010-02-18 2016-09-14 エフィミュヌＥｆｆｉｍｕｎｅ Anti-CD28 humanized antibody
US9045541B2 (en) * 2012-02-06 2015-06-02 Inhibrx Llc CD47 antibodies and methods of use thereof
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SG11201501464TA (en) 2012-08-31 2015-03-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
KR102170196B1 (en) 2013-02-06 2020-10-26 인히브릭스, 인크. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
BR112017010303A2 (en) 2014-11-18 2018-05-15 Janssen Pharmaceutica Nv cd47 antibodies, methods and uses
KR102489471B1 (en) * 2014-12-30 2023-01-18 셀진 코포레이션 Anti-CD47 Antibodies and Uses Thereof
JP2018535692A (en) * 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Anti-CD47 antibody and method of use

Also Published As

Publication number Publication date
ECSP19008417A (en) 2019-02-28
JP7120989B2 (en) 2022-08-17
US11427632B2 (en) 2022-08-30
WO2018009499A1 (en) 2018-01-11
CN109689684A (en) 2019-04-26
AU2017292752B2 (en) 2023-07-27
MX2019000172A (en) 2019-09-26
BR112019000166A2 (en) 2019-10-01
CA3029977A1 (en) 2018-01-11
AU2017292752A1 (en) 2019-01-24
IL264009A (en) 2019-01-31
CL2019000019A1 (en) 2019-06-28
KR20190035737A (en) 2019-04-03
EA201990218A1 (en) 2019-07-31
JP2019524087A (en) 2019-09-05
US20190241654A1 (en) 2019-08-08
CN109689684B (en) 2022-09-23
EP3481862A4 (en) 2020-08-12
CO2019001112A2 (en) 2019-02-19
EP3481862A1 (en) 2019-05-15
TW201811824A (en) 2018-04-01
SG11201811788SA (en) 2019-01-30
ZA201900070B (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CL2019002566A1 (en) Anti-phf-tau antibodies and their uses.
AR108975A1 (en) ANTIBODIES WITH LOW IMMUNOGENICITY AND ITS USES
CO2018011364A2 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
ECSP19050049A (en) ANTI-OX40 ANTIBODIES AND THEIR USES
ECSP19026178A (en) ANTI-PD-1 ANTIBODIES AND THEIR USES
CL2020003409A1 (en) Specific binding molecules for cd73 and manufacturing methods of the same (divisional of the application no. 201701154)
ECSP18095014A (en) BISPECIFIC BINDING PROTEINS THAT BIND AN IMMUNOMODULATING PROTEIN AND A TUMOR ANTIGEN
CO2018003436A2 (en) Agonist antibodies that specifically bind human cd40 and methods of use
MX2022012749A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies.
CL2017000278A1 (en) Bispecific t-cell activating antigen binding molecules
CY1124806T1 (en) ENANTI-CD40 ANTIBODIES AND USES THEREOF
CO2018002446A2 (en) Thymic stromal lymphopoietin (tslp) binding molecules and methods of using the molecules
BR112019012343A2 (en) il-11ra antibodies
CR20170095A (en) ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS RECIPROCAL REFERENCES WITH RELATED APPLICATIONS
BR112018012344A2 (en) antibodies that specifically bind to hla-dr and their uses
BR112019002579A2 (en) monovalent, asymmetric and tandem fab bispecific antibodies
BR112017012954A2 (en) antibody compositions and methods targeting bmp6
CR20180529A (en) ANTI-FACTOR ANTIBODIES BB OF THE COMPLEMENT AND USES OF THESE CROSSED REFERENCES
BR112018068671A2 (en) neutralizing monoclonal antibodies to il-25 and their uses
AR106132A1 (en) OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES